Mannitol Injection, USP, 25%

For Intravenous Use

DESCRIPTION
Mannitol Injection, USP, 25%, an osmotic diuretic, is a sterile, nonpyrogenic solution of mannitol in Water for Injection. It is a supersaturated solution at room temperature.

Each mL contains: Mannitol 250 mg; Water for Injection q.s. The osmolar concentration is 1372 mOsmol/L (calc.). It contains no antimicrobial agents. The pH of a 5% solution is between 4.5 and 7.0.

CLINICAL PHARMACOLOGY
Mannitol is an osmotic diuretic. After intravenous injection, it is confined to the extracellular space, metabolized only slightly and excreted rapidly by the kidneys. Approximately 80% of a 100 g dose appears in the urine in three hours. Mannitol is freely filtered by the glomeruli with less than 10% tubular reabsorption. It is not secreted by tubular cells. It induces diuresis by elevating the osmolarity of the glomerular filtrate and thereby hinders tubular reabsorption of water. Urinary output of water and excretion of sodium and chloride are enhanced. Mannitol is poorly absorbed from the gastrointestinal tract.

Mannitol Injection, USP, 25% is free of electrolytes and is used in urology as a nonhemolytic irritant. The amount of mannitol absorbed intravascularly during transurethral prostatic surgery is variable and depends primarily on the extent of the surgery. Such mannitol is excreted by the kidneys and produces osmotic diuresis.
INDICATIONS AND USAGE

For Intravenous Injection

Mannitol Injection, USP, 25% is indicated for the following therapeutic uses:

- in the prophylaxis of oliguria in surgical procedures and traumatic conditions involving renal insult;
- in the adjuvant treatment of oliguria or anuria;
- the promotion of diuresis in the supportive treatment of edema and ascites;
- the reduction of elevated cerebrospinal fluid pressure;
- in the adjunctive treatment in certain drug intoxications.

CONTRAINDICATIONS

Mannitol Injection, USP, 25% is contraindicated in the following:

- well-established anuria due to severe renal disease;
- severe pulmonary congestion or frank pulmonary edema;
- active intracranial bleeding except during craniotomy;
- severe dehydration;
- progressive renal damage or dysfunction after institution of mannitol therapy, including increasing oliguria and azotemia;
- progressive heart failure or pulmonary congestion after mannitol therapy is started.

WARNINGS

In severe impairment of renal function, a test dose should be given (see DOSAGE AND ADMINISTRATION). A second test dose may be given if there is an inadequate response. No more than two test doses should be attempted.
Excessive loss of water and electrolytes may lead to serious imbalances. Serum sodium and potassium should be carefully monitored during mannitol therapy.

The diuresis after rapid infusion of mannitol may increase preexisting hemoconcentration. With continued use of mannitol, a loss of water in excess of electrolytes can cause hypernatremia.

Shift of sodium-free intracellular fluid into the extracellular compartment after mannitol infusion may lower serum sodium concentration and aggravate preexisting hyponatremia.

Closely monitor the urine output and discontinue mannitol infusion promptly if output is low. Inadequate urine output results in accumulation of mannitol, expansion of extracellular fluid volume, and could result in water intoxication or congestive heart failure. Renal function must be closely monitored during mannitol infusion.

Mannitol solution must be used with caution in patients with significant cardiopulmonary or renal dysfunction.

Irrigating solutions used in transurethral prostatectomy have been shown to enter the systemic circulation in relatively large volumes, exert a systemic effect and may significantly alter cardiopulmonary and renal dynamics.

**PRECAUTIONS**

**General**

Crystals, if present in Mannitol Injection, USP, 25%, may be dissolved by placing the vial in a hot water bath maintained between 60 °C to 80 °C with occasional shaking. The resulting solution should be allowed to cool to body temperature before injection. **NOTE: Use of any other method to heat the vial may result in its explosion.**
An administration set with a filter should be used for intravenous infusions of solutions containing 20% or more of mannitol.

The cardiovascular status should be carefully evaluated before mannitol is administered by rapid intravenous injection, or before and during transurethral resection since expansion of extracellular fluid may lead to fulminating congestive heart failure. By sustaining diuresis, mannitol may obscure and intensify inadequate hydration or hypovolemia.

Unless it is essential, electrolyte-free mannitol solutions should not be combined with blood. When it is essential to give the combination, at least 20 mEq of sodium chloride should be added to each litre of mannitol solution to avoid pseudo-agglutination. The contents of opened containers should be used promptly and unused contents should be discarded.

A white flocculent mannitol precipitate may result from contact with PVC surfaces which act as nuclei for rapid rate crystallization of small crystals. This condition has also been reported to occur when mannitol has come in contact with other plastic and rough glass surfaces. Attempting to resolubilize the white flocculent precipitate with the aid of heat is not useful because crystallization may recur in a short period of time.

**Carcinogenesis, Mutagenesis, Impairment of Fertility**

In an early study of 1, 5 or 10% mannitol, given for 94 weeks in the diet of Wistar rats, a low incidence of benign thymomas occurred in females which was apparently treatment-related. A subsequent life-time study at similar dose levels in Sprague-Dawley, Fischer and Wistar rats revealed no carcinogenic effect in the thymus.

Mannitol had no mutagenic activity in a series of *in vitro* and *in vivo* test systems.

Adequate studies measuring the effects of mannitol on fertility have not been done.
**Pregnancy**
Teratogenic studies in the mouse, rat and rabbit at oral doses up to 1,600 mg / kg did not reveal harm to the fetus or adverse effects on reproduction due to mannitol. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.

**Nursing Mothers**
It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when mannitol is given to a nursing mother.

**Pediatric Use**
Dosage requirements in children below the age of 12 years have not been established.

**ADVERSE REACTIONS**
Reactions are infrequent and may include:

**Metabolic:** fluid and electrolyte imbalance, acidosis, dehydration

**Gastrointestinal:** dryness of mouth, nausea, vomiting, diarrhea

**Genitourinary:** osmotic nephrosis, urinary retention

**Central nervous system:** headache, convulsions, dizziness

**Special senses:** blurred vision, rhinitis

**Cardiovascular:** pulmonary edema, edema, hypotension, hypertension, tachycardia, angina-like chest pains

**Dermatologic:** skin necrosis, thrombophlebitis

**Hypersensitivity:** urticaria

**Miscellaneous:** thirst, arm pain, chills, fever.
DOSAGE AND ADMINISTRATION

For Intravenous Injection

General Recommendations: Give Mannitol Injection, USP, 25% only intravenously. The total dosage, concentration and rate of administration should be governed by the nature and severity of the condition being treated, fluid requirement and urinary output. Usual adult dosage ranges from 50 to 200 g in 24 hours, but in most instances, an adequate response will be achieved at a dosage of approximately 100 g in 24 hours. The rate is usually adjusted to maintain an adequate urine flow (at least 30 to 50 mL / hr).

Test Dose: In marked oliguria or inadequate renal function, a test dose of mannitol should be given. The test dose may be approximately 0.2 g / kg (about 50 mL of a 25% solution) infused in three to five minutes to produce an adequate urine flow (at least 30 to 50 mL / hr). If urine flow does not increase within two or three hours, a second test dose may be given. If there is an inadequate response, the patient should be re-evaluated.

Prevention of Acute Renal Failure (Oliguria): When used during surgery, immediately postoperatively or following trauma, 50 to 100 g of mannitol as a 5 to 25% solution may be given. The concentration and amount will depend upon the fluid requirements of the patient. Following suspected or actual hemolytic transfusion reactions, 20 g of mannitol may be given intravenously over a five-minute period to provoke diuresis. If diuresis does not occur, the 20 g dose may be repeated. If there is an adequate urine flow (30 to 50 mL / hr), then intravenous fluids containing not more than 50 to 75 mEq of sodium per litre should be given in sufficient volume to match the desired urine flow (100 mL / hr) until fluids can be taken orally.

Treatment of Oliguria: The usual dose for treatment of oliguria is 50 to 100 g as a 15 to 25% solution.
**Reduction of Elevated Cerebrospinal Fluid Pressure:** A 25% solution of mannitol is recommended since its effectiveness depends on establishing intravascular hyperosmolarity. When used before or after surgery, a total dose of 1.5 to 2 g/kg can be given over a period of 30 to 60 minutes. Careful evaluation must be made of the circulatory and renal reserve prior to and during use of mannitol at this relatively high dose and rapid infusion rate. Careful attention must be paid to fluid and electrolyte balance, body weight, and total input and output before and after infusion of mannitol. Evidence of reduced cerebral spinal fluid pressure may be observed within 15 minutes after starting infusion.

**Urinary Excretion of Toxic Substances:** Mannitol in 5 to 25% solutions is used as an infusion as long as indicated if the level of urinary output remains high. The concentration will depend upon the fluid requirement and urinary output. Intravenous water and electrolytes must be given to replace the loss of these substances in the urine, sweat and expired air. If benefits are not observed after 200 g of mannitol are given, discontinue it.

<table>
<thead>
<tr>
<th>Concentration</th>
<th>How Prepared</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test dose</td>
<td>Use as supplied (25%)</td>
</tr>
<tr>
<td>5%</td>
<td>50 mL of mannitol plus 200 mL</td>
</tr>
<tr>
<td>10%</td>
<td>50 mL of mannitol plus 75 mL</td>
</tr>
<tr>
<td>15%</td>
<td>50 mL of mannitol plus 33.3 mL</td>
</tr>
<tr>
<td>20%</td>
<td>50 mL of mannitol plus 12.5 mL</td>
</tr>
<tr>
<td>25%</td>
<td>Use as supplied</td>
</tr>
</tbody>
</table>

Addition of potassium or sodium chloride to mannitol solutions of 20% or greater may cause precipitation of mannitol.
AVAILABILITY OF DOSAGE FORMS

C1550  Mannitol Injection, USP, 25% in a 50 mL single-dose flip-top vial in packages of 25.

Use only if solution is clear and if seal is intact and undamaged. Warm if crystallization has occurred. If all crystals cannot be completely dissolved, the solution should not be used.

Store at controlled room temperature, between 15 °C – 30 °C (59 °F – 86 °F). Protect from freezing.

Preservative Free. Discard unused portion.

Fresenius Kabi Canada Ltd.
165 Galaxy Blvd, Suite 100
Toronto, ON M9W 0C8

Questions or concerns? 1-877-821-7724

April 2017

Fresenius Kabi is a registered trademark of Fresenius SE.